Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Medivir AB ( (SE:MVIR) ) just unveiled an update.
Medivir AB has announced an extraordinary general meeting for its shareholders, scheduled for November 10, 2025, in Stockholm. This meeting will allow shareholders to exercise their voting rights either in person, by proxy, or through postal voting, with specific instructions and deadlines provided to ensure participation. This announcement is significant as it reflects Medivir’s commitment to shareholder engagement and transparent governance practices, potentially impacting its operational strategies and stakeholder relations.
The most recent analyst rating on (SE:MVIR) stock is a Buy with a SEK54.00 price target. To see the full list of analyst forecasts on Medivir AB stock, see the SE:MVIR Stock Forecast page.
More about Medivir AB
Medivir AB is a pharmaceutical company based in Sweden, focusing on the development of innovative treatments for cancer. The company is known for its expertise in protease inhibitor design and nucleoside and nucleotide science, aiming to address unmet medical needs in oncology.
Average Trading Volume: 215,661
Technical Sentiment Signal: Strong Sell
Current Market Cap: SEK159.7M
For an in-depth examination of MVIR stock, go to TipRanks’ Overview page.